Martine Clozel Selected Research

Bosentan (Tracleer)

11/2015	Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
11/2014	Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
1/2012	Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
1/2010	The cardiovascular physiology and pharmacology of endothelin-1.
6/2007	A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.
6/2006	Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.
1/2005	Role of endothelin in fibrosis and anti-fibrotic potential of bosentan.
5/2004	Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.
7/2003	Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat.
1/2003	Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martine Clozel Research Topics

Disease

14	Pulmonary Arterial Hypertension 01/2018 - 01/2003
8	Pulmonary Hypertension 11/2015 - 01/2003
6	Hypertension (High Blood Pressure) 07/2022 - 11/2002
5	Hypertrophy 01/2019 - 01/2003
4	Heart Failure 04/2002 - 01/2002
3	Cardiovascular Diseases (Cardiovascular Disease) 09/2015 - 12/2007
3	Proteinuria 12/2008 - 07/2003
2	Vascular Remodeling 07/2022 - 11/2015
2	Multiple Sclerosis 03/2019 - 12/2017
2	Autoimmune Diseases (Autoimmune Disease) 12/2017 - 05/2011
2	Edema (Dropsy) 01/2017 - 05/2011
2	Malaria 10/2016 - 01/2016
2	Inflammation (Inflammations) 05/2011 - 01/2003
2	Nausea 10/2010 - 06/2007
2	Ischemia 12/2008 - 10/2004
2	Headache (Headaches) 06/2007 - 04/2002
2	Disease Progression 06/2007 - 01/2003
2	Body Weight (Weight, Body) 06/2006 - 03/2002
2	Fibrosis (Cirrhosis) 01/2005 - 01/2003
2	Cardiomegaly (Heart Hypertrophy) 11/2002 - 01/2002
2	Myocardial Infarction 03/2002 - 01/2002
1	Obstructive Sleep Apnea 07/2022
1	Obesity 07/2022
1	Sleep Initiation and Maintenance Disorders (Insomnia) 10/2021
1	Asthma (Bronchial Asthma) 01/2020
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 03/2019
1	Chronic Disease (Chronic Diseases) 03/2019
1	Pain (Aches) 01/2018
1	Autoimmune Diseases of the Nervous System 12/2017
1	Thrombosis (Thrombus) 10/2017
1	Infections 10/2016
1	Ventricular Remodeling 11/2015
1	Atrioventricular Block 01/2013
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2013
1	Hypersensitivity (Allergy) 05/2011
1	Arthritis (Polyarthritis) 05/2011
1	Kidney Diseases (Kidney Disease) 04/2011
1	Vomiting 10/2010
1	Right Ventricular Hypertrophy 09/2009
1	Reperfusion Injury 12/2008
1	Coronary Artery Disease (Coronary Atherosclerosis) 12/2007
1	Peripheral Arterial Disease 12/2007

Drug/Important Bio-Agent (IBA)

12	Endothelins (Endothelin)IBA 07/2022 - 03/2002
12	Bosentan (Tracleer)FDA Link 11/2015 - 03/2002
10	Endothelin Receptor AntagonistsIBA 07/2022 - 04/2002
5	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2018 - 10/2010
5	Endothelin Receptors (Endothelin Receptor)IBA 01/2017 - 01/2002
5	macitentanIBA 10/2016 - 12/2008
4	ponesimodIBA 03/2019 - 05/2011
4	selexipagIBA 01/2018 - 10/2010
4	tezosentanIBA 12/2008 - 01/2002
3	AldosteroneIBA 07/2022 - 01/2005
3	Epoprostenol ReceptorsIBA 01/2018 - 09/2015
3	Sphingosine-1-Phosphate ReceptorsIBA 12/2017 - 05/2011
3	MonocrotalineIBA 10/2015 - 06/2006
2	aprocitentanIBA 07/2022 - 01/2019
2	Antihypertensive Agents (Antihypertensives)IBA 07/2022 - 09/2009
2	Vasoconstrictor AgentsIBA 07/2022 - 01/2003
2	CatecholaminesIBA 07/2022 - 06/2006
2	SaltsIBA 07/2022 - 01/2019
2	Therapeutic UsesIBA 03/2019 - 01/2013
2	acetamideIBA 01/2018 - 10/2010
2	treprostinil FDA Link 01/2017 - 12/2012
2	ambrisentan FDA Link 01/2012 - 05/2004
2	Biomarkers (Surrogate Marker)IBA 04/2011 - 02/2007
2	Endothelin-1 (Endothelin 1)IBA 01/2007 - 01/2004
2	1- (2- (4- benzyl- 4- hydroxypiperidin- 1- yl)ethyl)- 3- (2- methylquinolin- 4- yl)ureaIBA 03/2006 - 10/2004
1	Orexin Receptor AntagonistsIBA 10/2021
1	daridorexantIBA 10/2021
1	Interleukin-5 (Interleukin 5)IBA 01/2020
1	Interleukin-13IBA 01/2020
1	Myelin Basic ProteinIBA 03/2019
1	Dimethyl FumarateIBA 03/2019
1	Myelin-Oligodendrocyte GlycoproteinIBA 03/2019
1	Acetates (Acetic Acid Esters)FDA Link 01/2019
1	ReninIBA 01/2019
1	Desoxycorticosterone (Deoxycorticosterone)IBA 01/2019
1	Desoxycorticosterone Acetate (DOCA)FDA Link 01/2019
1	cenerimodIBA 12/2017
1	Fingolimod Hydrochloride (FTY720)FDA Link 12/2017
1	selatogrelIBA 10/2017
1	TicagrelorIBA 10/2017
1	Arginine Vasopressin (Argipressin)IBA 01/2017
1	ACT-451840IBA 10/2016
1	Antimalarials (Antimalarial Agents)IBA 01/2016
1	Endothelin B ReceptorIBA 11/2015
1	sarafotoxins s6IBA 10/2015
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2013
1	(4- ((5,6- diphenylpyrazin- 2- yl)(isopropyl)amino)butoxy)acetic acidIBA 12/2012
1	Vasodilator Agents (Vasodilators)IBA 12/2012
1	compound 17IBA 09/2012
1	CytokinesIBA 05/2011
1	Amino Acids FDA Link 01/2010
1	Peptides (Polypeptides)IBA 01/2010
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 12/2007
1	AngiotensinsIBA 12/2007

Therapy/Procedure

6	Therapeutics 01/2020 - 06/2007
2	Oral Administration 12/2017 - 01/2013
1	Immunomodulation 05/2011
1	Vascular Surgical Procedures 12/2007